Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9–13 Years of Age in Malaysia

Abstract

Supplemental Digital Content is available in the text.

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types

“…For example, assays may be critical for assessing immunogenicity during vaccine coadministration trials, which could take place long after a vaccine has become part of national vaccination programs. Such trials assess the feasibility of concomitantly administering two different vaccines at the same visit, with the aim of maximizing vaccine coverage by administering a newer vaccine with a vaccine that is already part of an existing vaccination program ( 26 – 28 ). In cases of vaccine coadministration trials, it is important to have modernized assays that are capable of reproducibly delineating the immunogenicity associated with each respective vaccine so as to assure effectiveness and the lack of immune interference within target populations.…”

Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021

“…No safety issues or decreased immunogenicity were associated with coadministration of these vaccines. Trials are ongoing to evaluate concomitant and sequential administration of the Dengvaxia vaccine with a human papillomavirus vaccine among children aged 9-13 years in Malaysia (69) and among children aged 9-14 years in Mexico (70), as well as coadministration with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine among persons aged 9-60 years (71).…”